| Manufacturer ▼ | Drug Name | Indication | Stage | Status | Route of Administration | Drug Class |
|---|---|---|---|---|---|---|
| Mirum Pharmaceuticals Inc. | Maralixiba - (RISE) | Progressive Familial Intrahepatic Cholestasis, Alagille Syndrome | Phase 2 | Ongoing | Oral | Genetic Disorder |
| Moderna Inc. | mRNA-1010 - (P304) | Seasonal influenza | BLA Filing | Withdrawn | Intramuscular | Respiratory |
| Moderna Inc. | mRNA-1083 | COVID-19 | NDA Filing | Ongoing | Intramuscular | COVID-19 |
| Moderna Inc. | Trivalent‚ÄØ(mRNA-1403) - (Nova 301) | Norovirus | Phase 3 | Ongoing | Intramuscular | N/A |
| Moderna Inc. | V940-001 (mRNA-4157) with KEYTRUDA (pembrolizumab) - (INTerpath-002) | Personalized cancer vaccine, high-risk melanoma, lung cancer | Phase 3 | Data Released | Intravenous | Oncology |
| Moderna Inc. | mRNA-1608 | Herpes simplex virus (HSV) | Phase 3 | Trial Discontinued | Intramuscular | Antiviral |
| Moderna Inc. | mRNA-1468 | Shingles (herpes zoster) | Phase 3 | Trial Discontinued | Intramuscular | Antiviral |
| Moderna Inc. | mRNA-3705 | Methylmalonic Acidemia | Phase 3 | Trial Planned | Intravenous | Genetic Disorder |